Scholar Rock Holding Corporation's apitegromab shows promise for SMA treatment, aims for 2025 launch. Click for my updated ...

FDA-approved treatments for spinal muscular atrophy differ in their mechanisms of action, safety profiles, and administration ...

Despite significant advancements in spinal muscular atrophy (SMA) management, unmet needs persist, especially for patients ...

Affordable generic version of SMA drug Risdiplam soon available in India, offering hope to patients and activists.

The open-label STRENGTH study assessed the safety, tolerability, and efficacy of OAV101 IT in 27 patients with SMA who had previously discontinued nusinersen or risdiplam. Results found that the total ...

0.51 points in the sham control arm. In the Phase IIIb STRENGTH study, treatment with OAV101 IT in patients who have discontinued treatment with nusinersen or risdiplam demonstrated stabilization ...

tolerability and efficacy of OAV101 IT in patients with SMA aged two to less than 18 years who had discontinued treatment with nusinersen or risdiplam. Key findings: OAV101 IT demonstrated a ...

0.51 points in the sham control arm (P=0.0074).1-5 In the phase IIIb STRENGTH study, treatment with OAV101 IT in patients who have discontinued treatment with nusinersen or risdiplam demonstrated ...

Novartis also shared results from the open-label phase 3b STRENGTH study of OAV101 IT in SMA patients aged two to less than 18 years who had discontinued treatment with nusinersen or risdiplam, which ...

and Tysabri (natalizumab), as well as blockbuster spinal muscular atrophy therapy Spinraza (nusinersen). Biogen will retain its commercial rights to the biosimilars already brought to market ...

Along with Zolgensma – which made its debut in 2019 – Biogen has had approval to market its antisense-based therapy Spinraza (nusinersen) since 2016, while Roche got a green light for its ...